| 1 |
34431470 | Prospects of Treating Prostate Cancer through Apalutamide: A Mini-Review. | 2022 |
1 |
| 2 |
34449248 | A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. | 2022 Jan 6 |
3 |
| 3 |
34510570 | Maculopapular-type drug eruptions caused by apalutamide: case series and a review of the literature. | 2022 Feb |
1 |
| 4 |
35020444 | Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. | 2022 May |
1 |
| 5 |
35091711 | NEAR trial: A single-arm phase II trial of neoadjuvant apalutamide monotherapy and radical prostatectomy in intermediate- and high-risk prostate cancer. | 2022 Jan 28 |
1 |
| 6 |
35390118 | Targeting the androgen receptor signaling pathway in advanced prostate cancer. | 2022 Apr 7 |
2 |
| 7 |
35553247 | Decisions and dilemmas in non-metastatic castration-resistant prostate cancer management. | 2022 May 13 |
1 |
| 8 |
35579577 | Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. | 2022 May |
1 |
| 9 |
33003959 | The development of apalutamide for the treatment of prostate cancer. | 2021 Mar |
3 |
| 10 |
33140306 | Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer. | 2021 Mar |
1 |
| 11 |
33470111 | Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC). | 2021 Jan 28 |
2 |
| 12 |
33620092 | Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. | 2021 Jun |
1 |
| 13 |
33981146 | Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From "All-Comers" to "Personalized" Approach. | 2021 |
1 |
| 14 |
34080386 | [Management of metastatic hormone-naive prostate cancer at diagnosis]. | 2021 May |
1 |
| 15 |
34128827 | Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. | 2021 Jul 15 |
2 |
| 16 |
34144936 | Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan. | 2021 Sep |
1 |
| 17 |
34310904 | Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. | 2021 Sep |
1 |
| 18 |
34354111 | Conformational dynamics of androgen receptors bound to agonists and antagonists. | 2021 Aug 5 |
1 |
| 19 |
34422225 | Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer. | 2021 Aug 12 |
2 |
| 20 |
34526471 | Maculopapular Drug Eruption Caused by Apalutamide: Case Report and Review of the Literature. | 2021 Sep 14 |
1 |
| 21 |
34526701 | Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer. | 2021 Dec |
1 |
| 22 |
34734294 | [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?] | 2021 Dec |
1 |
| 23 |
34884545 | Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics. | 2021 Nov 25 |
1 |
| 24 |
31002873 | Androgen receptor in breast cancer: A wolf in sheep's clothing? A lesson from prostate cancer. | 2020 Feb |
2 |
| 25 |
31844181 | A review of prostate cancer treatment impact on the CNS and cognitive function. | 2020 Jun |
2 |
| 26 |
32057540 | Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure. | 2020 Mar |
2 |
| 27 |
32356465 | Phase II open-label study investigating apalutamide in patients with biochemical progression after radical prostatectomy. | 2020 Jun |
1 |
| 28 |
32366670 | Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. | 2020 Jul 15 |
2 |
| 29 |
32456317 | Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer. | 2020 May 24 |
1 |
| 30 |
32466878 | Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells. | 2020 Aug |
3 |
| 31 |
32549073 | Clinical and Surgical Assistance in Prostate Cancer during the COVID-19 Pandemic: Implementation of assistance protocols. | 2020 Jul |
1 |
| 32 |
32930958 | Apalutamide: A Review in Metastatic Castration-Sensitive Prostate Cancer. | 2020 Oct |
6 |
| 33 |
33163409 | Androgen Receptor Signaling and Metabolic and Cellular Plasticity During Progression to Castration Resistant Prostate Cancer. | 2020 |
1 |
| 34 |
30209899 | Role of Androgen Receptor in Prostate Cancer: A Review. | 2019 Sep |
1 |
| 35 |
30462924 | Perspectives on the current and emerging chemical androgen receptor antagonists for the treatment of prostate cancer. | 2019 Feb |
2 |
| 36 |
30787101 | Apalutamide Absorption, Metabolism, and Excretion in Healthy Men, and Enzyme Reaction in Human Hepatocytes. | 2019 May |
1 |
| 37 |
31150574 | Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. | 2019 Jul 4 |
1 |
| 38 |
31359832 | Apalutamide: A new agent in the management of prostate cancer. | 2019 Dec |
1 |
| 39 |
31404966 | Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. | 2019 Aug 9 |
1 |
| 40 |
31489589 | Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer. | 2019 Sep |
4 |
| 41 |
31635359 | Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair. | 2019 Oct 18 |
1 |
| 42 |
31855178 | TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth. | 2019 Dec 19 |
1 |
| 43 |
33457063 | Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer. | 2019 Jul |
3 |
| 44 |
29110617 | Degradation of Androgen Receptor through Small Molecules for Prostate Cancer. | 2018 |
2 |
| 45 |
29420164 | Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. | 2018 Apr 12 |
1 |
| 46 |
29606109 | Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. | 2018 Apr 2 |
1 |
| 47 |
29626324 | Apalutamide: First Global Approval. | 2018 Apr |
2 |
| 48 |
29695920 | Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. | 2018 |
5 |
| 49 |
29856649 | Apalutamide: the established and emerging roles in the treatment of advanced prostate cancer. | 2018 Jun |
4 |
| 50 |
30574205 | Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. | 2018 Dec |
5 |